Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
Johnson and Johnson
Express Scripts
Colorcon

Last Updated: June 29, 2022

Investigational Drug Information for GTx-024


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug GTx-024?

GTx-024 is an investigational drug.

There have been 33 clinical trials for GTx-024. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are GTx, Columbia University, and Sanofi.

Recent Clinical Trials for GTx-024
TitleSponsorPhase
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy SubjectsAcasti Pharma Inc.Phase 1
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeUltragenyx Pharmaceutical IncPhase 1/Phase 2
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeGeneTx Biotherapeuics, LLC.Phase 1/Phase 2

See all GTx-024 clinical trials

Clinical Trial Summary for GTx-024

Top disease conditions for GTx-024
Top clinical trial sponsors for GTx-024

See all GTx-024 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
Johnson and Johnson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.